Protara Therapeutics, Inc. (NASDAQ:TARA – Get Rating) was the target of a large decrease in short interest in March. As of March 15th, there was short interest totalling 205,100 shares, a decrease of 30.4% from the February 28th total of 294,500 shares. Approximately 2.4% of the shares of the company are sold short. Based on […]
Protara Therapeutics (NASDAQ:TARA – Get Rating)‘s stock had its “buy” rating reissued by HC Wainwright in a report issued on Thursday, TipRanks reports. They presently have a $40.00 price objective on the stock. Shares of NASDAQ:TARA opened at $4.25 on Thursday. Protara Therapeutics has a 52-week low of $4.07 and a 52-week high of $18.86. […]
NEW YORK (AP) Protara Therapeutics, Inc. (TARA) on Wednesday reported a loss of $10.2 million in its fourth quarter. On a per-share basis, the New York-based company said it had a loss of 91 cents.
/PRNewswire/ SystImmune, Inc. a clinical-stage company developing innovative cancer therapeutics, including novel bi-specific, multi-specific antibodies,.
REDMOND, Wash., Feb. 10, 2022 /PRNewswire/ SystImmune, Inc. a clinical-stage company developing innovative cancer therapeutics, including novel bi-specific, multi-specific antibodies, and.